The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84) in the context of osteoporosis and bone density, published as a randomized controlled trial.

A 24-week, randomized, open-label, parallel group, phase IV trial was conducted in 81 postmenopausal women with primary osteoporosis (≥50 years of age, lumbar spine, or total hip T-score ≤-2.5 SD) to assess the effect of SR as compared to PTH(1-84) on bone formation markers P1NP and BSAP.

Patient-reported outcomes were collected to investigate the effect of treatment on quality of life (QoL).

Why It Was Studied

The researchers explored the effects of PTH(1-84) compared with strontium ranelate on bone remodeling as measured by bone remodeling markers in postmenopausal women with osteoporosis.

Measuring changes in biochemical markers of bone turnover induced by these agents can help in characterizing the action of PTH(1-84) and SR on bone remodeling.

Who Took Part

According to the abstract, 81 women were involved.

The age groups tagged for this paper are middle-aged adults, women only.

How the Study Was Run

The design is described as randomized, open-label and parallel-group.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Parathyroid Hormone (PTH 1-84) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Groups ran in parallel: each of the women stayed in one arm throughout.

The bone resorption marker CTX was also measured.

What Was Measured

The researchers explored the effects of PTH(1-84) compared with strontium ranelate on bone remodeling as measured by bone remodeling markers in postmenopausal women with osteoporosis.

Measuring changes in biochemical markers of bone turnover induced by these agents can help in characterizing the action of PTH(1-84) and SR on bone remodeling.

PubMed files the paper under topics including Austria, Biomarkers, Bone Density Conservation Agents, Bone Remodeling, Organometallic Compounds, Osteogenesis and Osteoporosis, Postmenopausal.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Parathyroid Hormone (PTH 1-84) in 81 women in people with osteoporosis and bone density.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2011 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Osteoporosis and bone density research.